Compare BCRX & PURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCRX | PURR |
|---|---|---|
| Founded | 1986 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 1995 | 2025 |
| Metric | BCRX | PURR |
|---|---|---|
| Price | $8.47 | $12.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $20.82 | $8.15 |
| AVG Volume (30 Days) | 4.2M | ★ 21.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 381.40 | N/A |
| EPS | N/A | ★ 3.21 |
| Revenue | ★ $25,186,000.00 | $9,460,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.55 | $148.78 |
| P/E Ratio | ★ N/A | $4.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.00 | $3.01 |
| 52 Week High | $11.22 | $14.76 |
| Indicator | BCRX | PURR |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 54.24 |
| Support Level | $8.04 | $10.74 |
| Resistance Level | $10.05 | $12.74 |
| Average True Range (ATR) | 0.32 | 1.02 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 35.56 | 44.60 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. HSI aims to provide capital-efficient and productive access to the HYPE token for U.S. and institutional investors, generating compounding shareholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement. HSI is positioned to become the HYPE-focused digital asset treasury vehicle capitalizing on Hyperliquid's rapid growth and providing exposure to fastest growing revenue pools in digital assets.